Worldwide Clinical Trials Partners With Every Cure
Worldwide Clinical Trials (Worldwide) has partnered with Every Cure.
Through this new partnership, Worldwide will serve as Every Cure’s clinical trial and drug development partner. The CRO will use its clinical development and rare disease know-how to assist in identifying links between rare diseases and generic drugs on the market—all facilitated through the nonprofit’s open-source database of drug-repurposing opportunities.
Every Cure was co-founded by Dr. David Fajgenbaum, Dr. Grant Mitchell, and Tracey Sikora in 2022.
Reference
Worldwide Clinical Trials Partners with Every Cure to Accelerate Discovery of Treatments for Rare Disease Patients. (2023, May 11). Business Wire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
